FLOW-LBBB: Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With/Without Cardiac Resynchronization Therapy

Sponsor
Ashkan Eftekhari (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05564689
Collaborator
(none)
60
24.1

Study Details

Study Description

Brief Summary

Cardiac resynchronization therapy (CRT) is an effective therapeutic strategy in patients with symptomatic heart failure (HF) patients with LVEF of ≤35% and left bundle branch block (LBBB). However, approximately one-third of CRT-recipients do not improve after therapy (non-responders), despite meeting the required criteria.

Previous studies have documented that the positive respons to CRT is related to the delayed electrical activation of the left ventricle in patients with LBBB. It has also been illustrated that non-ischemic CRT-candidates with LBBB demonstrate lower regional myocardial blood flow and metabolism in the septum. Additionally, it has been suggested that LBBB can lead to impaired coronary blood flow in the left anterior descending artery (LAD). This observation is based on an echocardiography-based study, that showed that the percentage of diastolic flow duration (%DD) in LAD was shorter in patients with LBBB compared to the control-group and patients with right-ventricular pacing.

It has been demonstrated that CRT has positive effects on septal myocardial perfusion in patients with HF and LBBB. The dominant hypothesis explaining this phenomenon is built on improved septal myocardial work after CRT-implantation, which leads to increased myocardial energy and therefore increased myocardial perfusion. In contrast, it has been suggested that due to re-established synchronous left ventricular electrical activation, CRT reduces the septal intramyocardial pressure in early diastole, leading to a relatively longer antegrade flow duration in LAD. Therefore, the aim of the study is to evaluate the effect of CRT on coronary blood flow in LAD in patients with non-ischemic HF and LBBB.

We hypothesize that increased LV-function after CRT not only is due to resynchronized LV ejection and filling, but also improved coronary flow.

The study aims to enroll 60 patients with heart failure due to non-ischemic dilated cardiomyopathy, LBBB, with or without CRT. All patients meeting the criteria will be recruited from the outpatient clinic at the Department of Cardiology, Aalborg University Hospital.

Invasive flow measurements in the LAD, including fractional flow reserve (FFR), absolute coronary flow and -reserve will be conducted with the CRT on and off, respectively.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Intracoronary flow and pressure

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Case-Only
Time Perspective:
Other
Official Title:
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With/Without Cardiac Resynchronization Therapy
Anticipated Study Start Date :
Sep 27, 2022
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients with or in need of CRT, left bundle branch block, without ischemic heart disease

Procedure: Intracoronary flow and pressure
Measurement of absolute coronary flow and resistance

Outcome Measures

Primary Outcome Measures

  1. Absolute coronary flow [15 min]

    Measurement of absolute coronary flow with/without CRT-function

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18

  • QRS ≥ 150 ms before implantation

  • Heart failure because of dilated cardiomypathy

  • Sinus rhythm

  • Stable medical therapy

  • LBBB

  • CRT device

Exclusion Criteria:
  • eGFR < 30 ml/min

  • Severe valvular heart disease

  • Permanent atrial fibrillation or atrial flutter

  • Prior PCI or CABG

  • Prior myocardial infarction

  • Heart failure due to ischemic heart disease

  • Other type of device (pacemaker, ICD)

  • Not able to give informed consent

  • Does not understand Danish

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ashkan Eftekhari

Investigators

  • Principal Investigator: Ashkan Eftekhari, Department of Cardiology, Aalborg University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ashkan Eftekhari, Interventional Cardiologist, Aalborg University Hospital
ClinicalTrials.gov Identifier:
NCT05564689
Other Study ID Numbers:
  • N-20220040
First Posted:
Oct 3, 2022
Last Update Posted:
Oct 3, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ashkan Eftekhari, Interventional Cardiologist, Aalborg University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2022